Navigation Links
Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market Worth $825 Million by 2017

DALLAS, May 27, 2013 /PRNewswire/ --

The "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market & Stable Isotopes [SPECT/PET Radioisotopes (Technetium, F-18)], [Beta/Alpha Radiation Therapy (I131, Y-90)], [Applications (Cancer/Oncology, Cardiac)] & (Deuterium, C-13) - Forecast to 2017" analyzes and studies the major market drivers, restraints, and opportunities in Japan, China, India, South Korea, Indonesia, Malaysia, Australia, New Zealand, and Rest of Asia.


  • 146 Market Data Tables
  • 27 Figures
  • 313 Pages and an in-depth Table of Contents on "Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market"

Early buyers will receive 10% customization on this report.

This report studies the Asia-Pacific nuclear medicine market over the forecast period of 2012-2017.

The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%.

Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimers disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75% to the Asia-Pacific Nuclear Medicine/Radiopharmaceuticals Market in 2012.

It is estimated that Tc-99m diagnostic procedures are expected to increase by more than 30% in the developing markets of the Asia-Pacific region, including India, Australia, and South Korea, between 2010 and 2030. The scheduled shutdown of the NRU reactor in Canada in 2016 and OSIRIS in France in 2018 will not have any major impact in the near future, since demand in this geographic region is compensated by local reactors such as ANSTO. Radiopharmaceuticals are under clinical trials to extend applications. For instance, preference for radiopharmaceuticals in neurological indications such as Alzheimer's, Parkinson's and dementia are increasing besides conventional applications such as cardiology and oncology. Furthermore, upcoming radioisotopes such as Ra-223 (Alpharadin) and Ga-68 possess huge potential for clinical applications.

Japan is the dominant Market for Diagnostic Radioisotopes with almost 40% share and has around 1,600 gamma cameras, installed in about 1,120 institutions; PET diagnosis has increased dramatically after 2002. The total number of PET institutes in Japan has increased around 6-7 times in the last 10 years. Among Asia-Pacific countries, India, South Korea, and Australia will be significant markets due to rising healthcare budgets and increasing popularity of different radiopharmaceuticals in various clinical indications. Processors such as ANSTO and other players from different geographies run reactors that are involved in the irradiation of U-235 to make crude isotopes. They follow various strategies to achieve sustainable growth, one of which is shifting to Low Enriched Uranium (LEU) from High Enriched Uranium (HEU). These key players were mainly involved in strategic agreements and contracts with other institutes and players, while generator manufacturers followed several strategies to maintain a sustainable supply chain.

Asia-Pacific held the largest share in the Global Stable Isotopes Market in 2012. The stable Isotopes Market was estimated at $56.1 million in 2012 and is poised to grow at 12.6% CAGR over the next five years. Growth of the Stable Isotope Market is driven by proteomics and system biology research and applications such as Nuclear Magnetic Resonance (NMR) and Mass Spectrometry (MS).

 Buy a copy of this Report @

 Browse Related Reports

About MarketsandMarkets

MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.

MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, semiconductors and electronics, aerospace & defense, agriculture industry.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Mr. Rohan
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Tel: +1-888-6006-441
Visit MarketsandMarkets Blog @
Connect with us on LinkedIn @

SOURCE MarketsandMarkets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Asia-Pacific Ophthalmic Devices Market Outlook to 2018 - Vision Care, Intraocular Lens (IOL), Cataract Surgery Devices, Ophthalmic Diagnostic Equipment, Refractive Surgery Devices, Vitreo Retinal Surgery Devices and Others
2. Top Five Growth Sectors in the Asia-Pacific Healthcare Market
3. Competitive Pricing Vital in the Asia-Pacific Digital and Computed Radiography Market, Finds Frost & Sullivan
4. Frost & Sullivan: Government Initiatives Drive Use of Electronic Medical and Health Records in Asia-Pacific
5. A Rise in the Number of the Aged in Asia-Pacific Widens the Market for Home Care Devices, Finds Frost & Sullivan
6. Philips demonstrates innovations in nuclear medicine imaging with a comprehensive portfolio of NM applications for IntelliSpace Portal
7. Karyopharm Therapeutics Initiates Two Phase 1 Trials with Oral KPT-330, the First Selective Inhibitor of Nuclear Export (SINE), in Patients with Advanced Cancers
8. International Isotopes Inc. Announces Nuclear Regulatory Commission Approval Of The Final Environmental Impact Statement For The Planned Depleted Uranium De-Conversion And Fluorine Extraction Processing Facility
9. Nuclear Medicine Information Systems and BioDose rebrand and relaunch as ec2 Software Solutions
10. TechPrecision Corporation Receives Nuclear Order for $860,000
11. European Nuclear Medicine / Radiopharmaceuticals Market Worth by Reach $1.6 Billion by 2017
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):